Purpose of review Loss of IKAROS in committed B cell precursors causes a block in differentiation while at the same time augments aberrant cellular properties, such as bone marrow stromal adhesion, self-renewal and resistance to glucocorticoid-mediated cell death. B cell acute lymphoblastic leukaemias originating from these early stages of B cell differentiation and associated with IKAROS mutations share a high-risk cellular phenotype suggesting that deregulation of IKAROS-based mechanisms cause a highly malignant disease process.
INTRODUCTION
B cell differentiation is characterized by a progressive loss in capacity to differentiate into alternative cell fates with a stepwise gain in immunoglobulin gene rearrangements that is coupled to the induction of discrete downstream signalling pathways (Fig. 1) . The desired outcome is activation of pre-B cell receptor (BCR) signalling that supports not only precursor cell expansion but also differentiation (reviewed by [1] ). The survival and proliferation of committed B cell precursors is normally constrained by an additional requirement for interleukin (IL)-7R signalling at the expansion phase (late pro-B/ large pre-B) followed by a second phase of pre-BCR signalling that mediates differentiation to a quiescent B cell precursor (small pre-B cell). This is concomitant with rearrangement of the immunoglobulin light chain locus (Igk), followed by B cell repertoire selection and maturation (Fig. 1) .
Acquisition of lymphoid lineage potential in multipotent progenitors and subsequent restriction into the B cell lineage is the collective work of a network of transcription factors (e.g. IKAROS, E2A, EBF1, FOXO1, PAX5 and IRF4) acting at discrete steps of this cellular process to induce and reinforce the molecular mechanisms that support this differentiation programme (reviewed by [2] [3] [4] ). Loss of function in individual regulators arrests differentiation at discrete steps both prior to and after B cell lineage commitment, arguing for their nonredundant participation in this process (Fig. 1) .
B-cell acute lymphoblastic leukaemia (B-ALL) is a malignancy of B cell precursor lymphocytes that affects both children and adults. Human leukaemias that derive from these early stages of differentiation ( Fig. 1 ) frequently harbour activating mutations in signalling factors and inactivating mutations in transcription factors highlighting the importance of balancing these activities for progression through the leukaemia-prone stages of B cell differentiation [5] [6] [7] [8] . Loss-of function or hypomorphic mutations in genes, including PAX5, TCF3/E2A, EBF1, IKZF1 (IKAROS) and IKZF3 (AIOLOS, a member of the IKAROS family), are common in B cell precursor ALL cases, suggesting that disruption of B-cell differentiation contributes to the pathogenesis of this disease [5] . However, mutations in IKZF1 appear to be uniquely associated with B-ALL that is refractory to standard treatment normally effective in 85% of the cases [9] . This suggests that IKAROS may serve a unique role in differentiation that when disrupted elevates B-ALL to a high-risk status. Here, we discuss recent insights into the role of IKAROS in B cell precursor differentiation.
BALANCING SELF-RENEWAL, PROLIFERATION AND B CELL DIFFERENTIATION
Assembly of a functional pre-BCR signalling complex in the late pro-B cell/ large pre-B cell is followed by a massive proliferative expansion supported by pre-BCR and IL-7R signalling [10] [11] [12] [13] [14] . This serves as Thus, it appears that during normal differentiation, a transient pre-B cell-stromal interaction is in place to support a limited self-renewing expansion and to prevent signalling that promotes differentiation.
KEY POINTS
Loss of IKAROS (in combination with its family member AIOLOS) arrests differentiation at the stromal-adherent self-renewing large pre-B cell (Fig. 1 ]. Importantly, a combination therapy with inhibitors for the ABL and FAK kinases shows promise in reducing adhesion properties and leukaemia initiating frequencies in human B-ALL [21 & ]. The role of IKAROS in promoting pre-B cell differentiation is reminiscent of its earlier role in multipotent progenitors wherein it is induces the potential for lymphoid differentiation by priming transcription of lymphoid lineage-promoting genes [22, 23] . There is also a significant overlap in genes and pathways that are negatively regulated by IKAROS both prior to (in the HSC and LMPP) and after B cell lineage commitment (in the large pre-B) [18 && ,23] (Fig. 2) . Thus, IKAROS is engaged in promoting differentiating and moderating self-renewal from the onset of haematopoiesis in multipotent progenitors through B cell lineage committed precursors by participating into similar regulatory mechanisms. Deregulation of these mechanisms produces arrested differentiation intermediates with exceptional properties such as cell adhesion and self-renewal.
A SILENT LANDSCAPE OF ENHANCERS MARKED BY IKAROS
IKAROS is located primarily at enhancer locations in stromal adherent large pre-B cells, suggesting that it controls differentiation by regulating the activity of these sites [24 && ]. In their majority, IKAROS enrichment sites are present in a relatively restricted chromatin environment that is marked by low levels of enhancer-prevalent histone modifications (e.g. H3K4me1 and H3K4me2) and lack of histone modifications that correlate with transcriptional activity (e.g. H3K27Ac). The chromatin profile at these IKAROS-bound enhancers is therefore indicative of an inactive enhancer status. These inactive enhancers also show little occupancy by B cell specific transcription factors (e.g. PAX5, EBF1), or general transcription factors (e.g. RNApII, MED1), and are in the vicinity of transcriptionally inactive genes [24 && ]. Remarkably, the majority of these enhancers acquire a highly permissive chromatin in IKAROS-deficient B cell precursors, are highly enriched with RNApII and MED1, and are associated with induction of genes that include core regulatory components of cell adhesion, actin cytoskeleton, small GTPases, Ras signal transduction and transcription (Fig. 3) [24 && ]. Loss of IKAROS is not the only contributing factor to the induction of these normally repressed regulatory domains and their associated genes. A group of extra-lineage transcription master regulators that are directly repressed by IKAROS in B cell precursors are strongly enriched at de-novo enhancers that frequently cluster in a superenhancer configuration in mutant cells (Fig. 3) . Super-enhancers are defined as clusters of binding sites for master transcription regulators, are highly enriched for active histone modifications and the Mediator complex, and are responsible for expression of genes that specify a new cell identity [25, 26, 27 && ]. Among the group of extra-lineage transcription factors were LMO2, associated with haematopoietic stem cell self-renewal, early haematopoietic lineage decisions as well as T and B cell precursor leukaemias [28, 29] ; YAP1 and TEAD (1/2), the nuclear effectors of the Hippo pathway implicated in growth and self-renewal in nonlymphoid cell types and responsible for super-enhancer activation through recruitment of the Mediator and the CDK9 elongation complex [30, 31 && ]; and LHX2 a pioneer factor in neuronal and skin epithelial stem cells [32, 33, 34 & ]. Notably, B cell master regulators (e.g. EBF1, PAX5, IRF4) that are normally excluded from the repressed enhancer landscape in wild-type large pre-B cells were also highly enriched at the de-novo enhancer and superenhancers in IKAROS-deficient pre-B cells. As this new network of transcription factors supports its own expression, loss of IKAROS sets in motion a powerful feed-forward regulatory loop that results in the rapid induction of both 'extra-lineage' transcription factors and their downstream targets (Fig. 3) [24 && ]. Knockdown studies of either 'extra-lineage' or B cell transcription factors in IKAROS-deficient pre-B cells confirmed that they work together to induce expression of genes associated with these de-novo regulatory elements (Fig. 4) . Thus, IKAROS not only represses expression of 'extra-lineage' transcription factors but also restricts B cell transcriptional regulators from accessing the regulatory elements of lineage-inappropriate genes. Intermingling of these normally distinct control regimens in the same cell can lead to induction of an aberrant network of super-enhancers with dire consequences for B cell differentiation. && ]. A circos diagram depicting overlap between upregulated genes (purple connecting lines) in IKAROS-deficient HSC, LMPP and large pre-B cells is shown on the left side. A heatmap of functional pathways supported by the IKAROS-repressed genes in these cell types is shown on the right side. The colour intensity of the heatmap is a measure of the P value that indicates the enrichment for a given pathway in the corresponding list of upregulated genes provided by a given experimental condition (e.g. in HSC, LMPP or large pre-B cell).
FIGURE 3.
Reciprocal regulation of enhancers and B cell lineage fidelity. IKAROS sets a highly permissive chromatin environment that defines super-enhancers at genes involved in pre-BCR signalling and differentiation. IKAROS also associates with the inactive enhancers of genes that support pathways such as cell adhesion, self-renewal and drug resistance normally affiliated with a nonlymphoid cell identity. Among the repressed IKAROS, gene targets are master transcription regulators prevalent in nonlymphoid cells that upon IKAROS loss become induced and cooperate with B cell transcription factors to activate a de-novo super-enhancer repertoire that supports the aberrant cellular properties of the mutant B cell precursors. Notably, these aberrant properties manifested in primary IKAROS pre-B cells are likely responsible for the high-risk status of leukaemias caused by activating mutations in tyrosine kinases (e.g. BCR-ABL, JAK2-PDGFR).
antagonism between strong enhancers (transcription) and PRC activity and support for an indirect IKAROS-PRC2 interaction [24 && ]. In the model presented in Fig. 3 , IKAROS and the PRC2 complex may contribute independently to the repression of a stem-epithelial transcriptional programme in large pre-B cells. Such a regulatory scenario occurs during development of the Drosophila embryo, with HUNCHBACK, the Drosophila homologue of IKAROS, initiating repression of the Hox gene locus and with Polycomb maintaining repression throughout development [35] [36] [37] [38] .
LESS BUT NOT LEAST; DEFINING PRE-B CELL DIFFERENTIATION SUPER-ENHANCERS
A smaller fraction of IKAROS sites in pre-B cells is associated with clusters of highly permissive, transcriptionally active enhancers (Fig. 3) . These sites are also highly enriched for B cell transcription factors, such as EBF1, PAX5, E2A and IRF4, as well as for the RNAPII and the Mediator complex, and are associated with genes that serve as key regulators of pre-B cell differentiation thereby satisfying the criteria for being super-enhancers [24 && ]. Key components of pre-BCR signalling, such as Sykb, CD79b, Blnk, Foxo1 and Ccnd3, whose loss-of-function mutations have been reported to arrest B cell differentiation [39] [40] [41] [42] [43] [44] , were associated with IKAROS super-enhancers and were downregulated in IKAROS-deficient pre-B cells (Fig. 3) [24 && ]. Importantly, these pre-B cell super-enhancers were functionally defined by IKAROS, as both their highly permissive chromatin and strong effect on transcription were attenuated upon loss of IKAROS despite the continued presence of other B cell master transcription regulators, such as EBF1 and PAX5, as well as the Mediator complex at these sites (Fig. 3) . Other B cell transcription factors may be important for the initial induction of this gene expression programme during development, but IKAROS is essential at this stage. IKAROS' role in the pre-B cell is to establish a highly permissive chromatin environment and promote super-enhancer activities and gene expression levels required for the pre-B cell transition.
CONCLUSION
The transcriptional regulatory mechanisms supported by IKAROS in B cell precursors not only set a new paradigm for regulation of lineage progression and fidelity but also provide new insights into the making of high-risk human B-ALL.
It appears that all of the early B cell master transcriptional regulators are engaged in promoting differentiation and preventing alternative cell fates. Nonetheless, the mode of action of such factors can dramatically change in a leukaemia setting in a manner that is dictated by the chromatin environment. EBF1 normally supports B cell differentiation acting through a B cell-specific chromatin landscape; however, it can be redirected to the new chromatin landscape that arises upon IKAROS loss and by doing so it promotes an altered high-risk B cell precursor cell identity. Thus, carefully evaluating the sequence of events surrounding the inactivation of a key transcriptional regulator such as IKAROS in the context of the transcriptional network through which it operates is critical for deciphering the networks driving normal differentiation and how they are utilized for malignant transformation. Do IKAROS mutations, normally considered a leukaemia-poor prognostic factor, lose this value when combined with EBF1 mutations?
It is important to establish whether ectopic expression of extra-lineage transcription factors normally upregulated upon loss of IKAROS is sufficient to override wild-type levels of IKAROS activity and induce the cryptic regulatory network in B cell precursors. Such studies may add new prognostic factors in the classification of high-risk B-ALL with intact IKAROS activity. Do these factors also negatively impact B cell differentiation and does their inactivation restore the original differentiation process?
Although loss of IKAROS reprograms the transcription and epigenetic landscape in support of an 'altered' pre-B cell fate, IKAROS-deficient pre-B cells are not leukaemic and are sensitive to an anoikis-type of cell death. Activating mutations in tyrosine kinases affiliated with growth factor receptor signalling provide stromal-independent survival of IKAROS-deficient pre-B cells and are responsible for transition to a highly aggressive leukemic state. Such leukaemia-associated signalling pathways may utilize the new epigenetic and transcription environment established by loss of IKAROS to achieve transformation. Transcription factors such as STAT5 whose activity is induced by leukaemogenic signalling may engage the de-novo enhancer landscape in the absence of Ikaros, hyperactivating and perhaps expanding the de-novo super-enhancer repertoire in support of a genetic programme that underscores highrisk leukaemia.
Continued effort on these basic research endeavours with special applications in human disease holds promise in not only setting new paradigms in cell differentiation but also in providing new therapies for leukaemia intervention, tailored to the epigenetic and transcriptional circuits of individual leukaemic clones.
